SAKAR · NSE
Sakar Healthcare Limited
₹1,179.8
+4.45% (+₹50.25)
Prev. close
₹1,129.55
Volume
1,47,455
Delivery %
64.5%
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Sakar Healthcare Limited
Sakar Healthcare Limited research, develops, manufactures, and sells pharmaceutical products in India. The company offers general and oncology products in various forms, such as liquid orals, cephalosporin tablets, capsules, dry powder syrups and injections, liquid injectable (SVP) in ampoules, vials and lyophilized injections, and oral solid dosages. It also exports its products to Southeast Asia, Asia, Africa-Anglo and Francophone, MENA countries, and the United States. Sakar Healthcare Limited was incorporated in 2004 and is based in Ahmedabad, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Sanjay Surendra Shah
Headquarters
Ahmedabad
Employees
435
Website
sakarhealthcare.comExchange
View on NSE ↗Key stats
Market cap
₹2,589.65 Cr
P/E ratio (TTM)
85.6
EPS (TTM)
₹13.78
Beta (1Y · daily vs NIFTY 50)
0.71
Beta (5Y · monthly vs NIFTY 50)
1.07
Shares float
50.89 L
EPS · quarter ended Mar 2026
₹4.96
Financial Performance
01 · Financials
FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based
05 · Capital Structure & Asset Utilization
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
07 · Debt Level & Coverage
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹94.74 Cr | ₹128.23 Cr | ₹133.36 Cr | ₹153.35 Cr | ₹177.58 Cr | ₹251.74 Cr | |
| EBITDA | ₹23.77 Cr | ₹31.50 Cr | ₹37.81 Cr | ₹41.54 Cr | ₹50.94 Cr | ₹71.18 Cr |
| ₹10.68 Cr | ₹15.18 Cr | ₹12.76 Cr | ₹11.67 Cr | ₹17.50 Cr | ₹30.48 Cr | |
| Diluted EPS | ₹6.87 | ₹10.09 | ₹6.86 | ₹5.63 | ₹7.95 | ₹13.7 |
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹177.79 Cr | ₹267.76 Cr | ₹336.34 Cr | ₹388.66 Cr | ₹415.26 Cr | ₹481.01 Cr | |
| — | — | ₹119.18 Cr | ₹79.35 Cr | ₹86.37 Cr | ₹70.53 Cr | |
| Stockholders' equity | ₹98.45 Cr | ₹127.45 Cr | ₹173.35 Cr | ₹262.33 Cr | ₹285.48 Cr | ₹324.45 Cr |
Fixed assets, Others, Total debt, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹14.58 Cr | ₹35.70 Cr | ₹33.34 Cr | ₹24.47 Cr | ₹34.03 Cr | ₹49.26 Cr | |
| Investing cash flow | ₹-46.83 Cr | ₹-90.37 Cr | ₹-74.38 Cr | ₹-51.54 Cr | ₹-30.71 Cr | ₹-28.35 Cr |
| ₹32.03 Cr | ₹54.62 Cr | ₹41.10 Cr | ₹27.44 Cr | ₹-3.48 Cr | ₹-20.96 Cr | |
| Capital expenditure | ₹-35.55 Cr | ₹-97.53 Cr | ₹-82.20 Cr | ₹-59.56 Cr | ₹-32.28 Cr | ₹-28.35 Cr |
| End cash position | ₹8.25 L | ₹2.98 L | ₹9.34 L | ₹46.55 L | ₹30.93 L | ₹25.76 L |
Debt issued, Debt repaid have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21–Jun 22(4Q) | Jul 22 | Sep 22–Dec 22(2Q) | Feb 23–Jun 23(3Q) | Sep 23–Sep 23(2Q) | Dec 23–Sep 24(4Q) | Dec 24–Mar 25(2Q) | Jun 25–Mar 26(4Q) | Jun 26 |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 67.54% | 62.10% | 62.10% | 60.72% | 54.15% | 53.15% | 53.58% | 52.86% | 52.52% |
| Public | 32.46% | 37.91% | 37.90% | 39.28% | 45.85% | 46.85% | 46.42% | 47.14% | 47.48% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Sakar Healthcare Limited | ₹2,486.92 Cr | ₹1,129.55 | 82.3 | 7.66 | 9.4% | 0.22 | +41.8% | — |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Concall transcripts
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Sakar Healthcare consolidated net profit rises 120.13% in the June 2026 quarter
Business Standard · 2 months ago